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Nonalcoholic steatohepatitis (NASH) is an important cause of liver-related morbidity and mortality. There are no
approved therapies, and the results of clinical trials have been difficult to compare due to inconsistent definitions of rele-
vant disease parameters in patients with NASH. The natural course of the disease has not been rigorously characterized,
particularly with respect to the contributions of underlying obesity, type 2 diabetes, and other comorbidities and the treat-
ments provided for these comorbidities. Efforts to perform analyses of pooled data are limited by heterogeneous case defi-
nitions used across studies to define disease states. There remains a major unmet need in the field to develop standardized
definitions for populations for interventional trials. Such definitions are expected to impact how endpoints for clinical trials
are constructed. The Liver Forum is a multistakeholder effort including US and European regulatory agencies, academic
investigators, professional and patient representative organizations, and industry to catalyze therapeutic development for
NASH by developing potential solutions to barriers to development. The Case Definitions Working Group was estab-
lished by The Liver Forum to evaluate the validity of case definitions for populations to be included in clinical trials for
NASH from a regulatory science perspective. Based on such analyses, specific recommendations are provided noting the
strengths and weaknesses of the case definitions along with knowledge gaps that require additional study. (HEPATOLOGY
2018;67:2001-2012)
Nonalcoholic fatty liver disease (NAFLD)affects one third of adults in Westernnations.(1) NAFLD may manifest histologi-
cally as a fatty liver (FL) or nonalcoholic steatohepatitis
(NASH). FL progresses slowly compared to NASH,
which is more likely to lead to progressive fibrosis and
cirrhosis.(2,3) NASH cirrhosis is rapidly increasing as
an indication for transplantation,(4) and while pharma-
cologic therapy is not yet available, NASH is increas-
ingly being targeted by drug development efforts.
Regulatory pathways for developing diagnostic tests
and therapeutic interventions for NASH require
granular understanding of disease course and associ-
ated clinical outcomes. Despite a plethora of litera-
ture, the variable case definitions, methods for
identification of subjects, and assessment of outcomes
limit the ability to anchor diagnostics and therapeutic
development on a robust model of the disease, imped-
ing assessment of diagnostics and benefit of therapeu-
tic interventions.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC, area under the receiver operating characteristic curve;
CAP, controlled attenuation parameter; FDA, Food and Drug Administration; FL, fatty liver; HVPG, hepatic venous pressure gradient; LSM, liver
stiffness measurement; MRE, magnetic resonance elastography; MRI-PDFF, magnetic resonance imaging–estimated proton density fat fraction;
NAFLD, nonalcoholic fatty liver disease; NAS, NAFLD activity score; NASH, nonalcoholic steatohepatitis; NASH CRN, NASH Clinical Research
Network; SAF, Steatosis–Activity–Fibrosis; VCTE, vibration-controlled transient elastography.
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The Liver Forum was established in 2014 following
a workshop sponsored by the US Food and Drug
Administration (FDA) and the American Association
for the Study of Liver Diseases(5) and provides a mech-
anism for dialogue between regulatory agencies and
other stakeholders in a neutral, collaborative, and non-
binding manner to accelerate development efforts for
NAFLD. The Liver Forum model involves collabora-
tion between the FDA, the European Medicines
Agency, academic investigators, industry stakeholders,
and patient representatives. A key priority identified
was the need for case definitions that meet regulatory
standards and are uniformly applicable across clinical
trials, which is essential for comparing the utility of
various therapies and demonstrating overall benefit of
therapeutic interventions. Standardized definitions will
facilitate integration of new diagnostic tools into the
overall drug development plan for NASH and will
allow future pooled analyses to robustly model the dis-
ease, taking into account effects of comorbidities and
their treatments.
The Case Definitions Working Group analyzed
existing literature, generated the “best” definitions
from a regulatory science perspective, and identified
gaps in the field. This article represents the working
group’s output, which has been presented to and cri-
tiqued by the overall Liver Forum membership. Rec-
ommendations put forth in this article are for the
purposes of regulatory science rather than clinical
practice guidance. These definitions and
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recommendations are nonbinding and do not repre-
sent official positions of the FDA or the European
Medicines Agency.
Methods
The working group was divided into subgroups to
evaluate the case definitions currently used for the fol-
lowing NAFLD phenotypes: (1) FL, (2) indeterminate
NASH, (3) NASH without fibrosis, (4) NASH
with early fibrosis, (5) NASH with bridging fibrosis,
(6) compensated cirrhosis, and (7) decompensated
cirrhosis.
Following a standardized discussion format, mem-
bers described the characteristic clinical phenotype,
liver histology, and means of noninvasive assessment.
The data were synthesized to summarize whether defi-
nitions were objective, quantifiable, analyzable using
quantitative approaches, sensitive to change, and logis-
tically feasible to operationalize in the context of multi-
center clinical trials. The relationship of definitions to
clinical outcomes was assessed from the literature. The
findings of the subgroups were discussed within the
larger working group and presented to Liver Forum
members for feedback. Consensus regarding optimal
definitions was not imposed but allowed to develop
through discussion. Areas requiring additional data
were identified.
We present the salient points raised by the working
group, which were reviewed within the FDA and the
European Medicines Agency for alignment with regu-
latory requirements. Our intent is to identify popula-
tions for pooled outcomes analyses, development of
patient-reported outcomes instruments, and
diagnostics. We include limited references due to space
constraints, with a list of additional references reviewed
provided in the Supporting Information.
Results
The core requirement defining NAFLD is docu-
mentation of hepatic steatosis that is not related to
excessive alcohol consumption. For the purpose of this
report, we assume that excessive alcohol consumption
has been excluded along with secondary causes of
hepatic steatosis (Supporting Information).
The subpopulations were collapsed into three broad
groups: (1) non-NASH, (2) NASH, and (3) NASH
cirrhosis. Each comprises several subcategories with
regard to clinical phenotype, histology, and noninva-
sive assessment.
The field of NAFLD is anchored by histological
assessment, and the National Institute of Diabetes
and Digestive and Kidney Diseases’ NASH Clinical
Research Network (CRN) system of grading disease
activity and staging fibrosis separately is the most
widely used and validated.(6) The Steatosis–Activity–
Fibrosis (SAF) reports but does not add the three
major histological features (steatosis, activity, and
fibrosis) into one formula, permitting greater granu-
larity(7); however, SAF has not been used in phase 2B
or 3 clinical trials. The Goodman classification com-
bines disease activity and fibrosis, with greater weight
given to advanced fibrosis.(8) It is the least validated
system and was included to determine if it adds utility
from a regulatory perspective to more established
systems.
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Non-NASH
Non-NASH includes the following histological sub-
types: FL, indeterminate NASH, and steatofibrosis.
Although described as separate entities for the sake of
regulatory classification, clinically they may represent
overlapping points on the histological spectrum. Com-
pared to NASH, FL has a low risk of liver-related out-
comes.(2,3,9) In indeterminate NASH, inflammation
and hepatocyte injury are present but atypical of defi-
nite steatohepatitis,(6) and steatofibrosis represents
non-NASH with fibrosis.(7) The natural history of
these phenotypes is not well characterized, and they
are included to distinguish them from NASH. If
future studies indicate that the natural histories of
these are similar to NASH, they may be reclassified as
“at-risk” disease states.
HISTOLOGY
All histological systems define non-NASH by the
presence of predominantly macrovesicular steatosis in
5% of hepatocytes.(6-8) There is relatively good intra-
observer and interobserver concordance with steatosis
assessment (Table 1).(6,10) While microvesicular stea-
tosis can occur in non-NASH, the presence of pre-
dominantly microvesicular steatosis should raise
concern for an alternate etiology.
Steatosis severity is categorized ordinally by all his-
tological systems (Supporting Table S1) and relates
linearly to techniques measuring hepatic triglyceride
content.(6-8,11) However, steatosis represents a contin-
uous process, and ordinal classification introduces
assessment errors at categorical boundaries. Despite
this, the intraobserver and interobserver concordance j
statistic for assessment of steatosis severity is 0.79 and
0.83, respectively.(6)
Mild lobular inflammation can coexist with steatosis
and does not appear to impact progression to cirrho-
sis.(6,12) While data quality is not optimal, steatosis
with grade 1 inflammation is included in the current
spectrum of non-NASH.
Indeterminate NASH, a subclassification only rec-
ognized by the NASH CRN system, is characterized
by grade 1 steatosis with mild lobular inflammation
and none to rare ballooning.(6) It can be associated
with varying amounts of fibrosis and may represent
more advanced disease than FL. Hepatic steatosis with
varying fibrosis stages short of cirrhosis in the absence
of inflammation and ballooning has been observed, but
no data link it to clinical outcomes.(6,7) This entity is
classified as steatofibrosis to allow for recognition and
classification. Better natural history data are needed on
these phenotypes before large-scale efficacy trials are
performed.
CLINICAL PHENOTYPE
No clinical phenotype permits identification of sub-
jects with non-NASH with high specificity. Many
subjects have one or more of the features of metabolic
syndrome, and polycystic ovarian syndrome may be
present in women.(13,14) Although common, overt
insulin resistance is not a diagnostic requisite.(14,15)
NONINVASIVE DIAGNOSIS
Aggregate scores from routine bioclinical data have
been investigated for their accuracy in predicting stea-
tosis (Table 2). The most promising include the FL
index, the hepatic steatosis index, the NAFLD-liver
fat score, the visceral adiposity index, the lipid
TABLE 2. Accuracy of Noninvasive Biomarkers in Diagnosing and Quantifying Hepatic Steatosis
Criteria Models CK-18 Ultrasound CAP MRI/MRS
Objective Yes Yes Yes Yes Yes
Subjective No No Yes No No
Quantifiable (separation of steatosis grade) No No No No Yes
Interobserver reliability N/A N/A Moderate Moderate High
Sensitive to change Unknown Unknown Unknown Unknown Yes
Used in clinical trials No No No No Yes
Abbreviations: CK-18, cytokeratin 18; MRS, magnetic resonance spectroscopy; N/A, not analyzed.
TABLE 1. A Comparison of the Histological Schema for
Grading Steatosis
Criteria NASH CRN SAF Goodman
Objective Yes Yes Yes
Subjective No No No
Quantifiable Yes Yes Yes
Sensitive to change Yes Unknown Unknown
Externally reproducible Yes Yes No
Used in clinical trials Multiple None None
SIDDIQUI, HARRISON, ET AL. HEPATOLOGY, May 2018
2004
accumulation product, and the triglyceride3 glucose
index.(16) The sensitivity and specificity of these for
detecting >5% and >33% steatosis are summarized in
Supporting Table S2. While not sufficiently accurate
for use as inclusion criteria, they may be used to enrich
populations screened. No circulating biomarkers,
including serum aminotransferases, are sufficiently
accurate as stand-alone measures of hepatic steatosis
for clinical trials.
IMAGING MODALITIES
Ultrasonography relies on increased hepatic echoge-
nicity and blurring of deep vessels and is a sensitive but
relatively nonspecific way to identify steatosis(17) (Sup-
porting Table S2); however, sensitivity drops when
used to detect 5%-20% steatosis.(18) The hepatorenal
index measures the mean ratio of echo intensities of
the liver and renal cortex and is highly sensitive and
specific in detecting >5% hepatic steatosis(19) (Table
2). While unsuitable as an entry criterion for enroll-
ment in advanced-phase NASH clinical trials, it may
be useful in identifying patients for proof-of-concept
trials.
Vibration-controlled transient elastography (VCTE)
assesses steatosis by reporting the loss of ultrasound sig-
nal through the liver, which is reported as the controlled
attenuation parameter (CAP). In a meta-analysis, CAP
had sensitivity and specificity of 78% and 79%, respec-
tively, for detecting S1 steatosis.(20) A CAP> 236
dB/m has sensitivity and specificity of 82% and 91%,
respectively, for detecting steatosis.(21) However, CAP
is less robust in discriminating between steatosis grades,
with an area under the receiver operating characteristic
curve (AUROC) of 0.73 and 0.70 for distinguishing S3
versus S0-2 and S2-3 versus S0-1, respectively(22)
(Table 2). CAP can be used as an enrichment tool along
with elastography to identify subjects for (1) biopsy for
advanced-phase trials, (2) proof-of-concept trials, or (3)
in trials in subjects with metabolic syndrome(23) where
NAFLD as a covariate needs to be documented.
Magnetic resonance spectroscopy and magnetic res-
onance imaging–estimated proton density fat fraction
(MRI-PDFF) quantify steatosis (Supporting Table
S2). Although magnetic resonance spectroscopy is
highly accurate, it only measures fat in small regions of
interest, while MRI-PDFF allows mapping of the
entire liver.(24,25) Both have been validated against
hepatic triglyceride content and histological assessment
of steatosis(26,27) and are sensitive to change.(25,28)
MRI-PDFF is reproducible across scanners of varying
field strength(24,25,28) and outperformed CAP in stea-
tosis detection.(21,22,29) MRI-PDFF is a validated
modality that can be used in early-phase studies to
detect and assess change in steatosis (Table 2).
In summary, histological assessment represents the
current standard for detecting hepatic steatosis. Non-
NASH is distinguished from NASH by having steato-
sis along with no or minimal disease activity. MRI-
PDFF is an accurate and sensitive method for steatosis
assessment and quantification and useful in early-phase
studies evaluating drug efficacy on steatosis. FL, inde-
terminate steatohepatitis, and steatofibrosis are histo-
logical phenotypes whose natural histories are not well
defined. These populations may be studied where spe-
cific questions regarding these phenotypes are posed or
to confirm if responses to treatment are similar to those
with NASH.
NASH
The broad category of NASH includes definite
NASH, NASH with early fibrosis (stages 1a,1b, 1c, 2;
Supporting Table S1), and NASH with bridging
fibrosis. NASH with cirrhosis is considered separately
because the clinical, laboratory, histological, and imag-
ing phenotype along with goals of treatment and study
design are different from those in patients with precir-
rhosis NASH.
HISTOLOGY
The NASH CRN system defines NASH by a pat-
tern of injury composed of steatosis, lobular inflamma-
tion, and ballooning degeneration.(6) The SAF system
requires a grade of 1 or higher for steatosis, lobular
inflammation, and ballooning.(7) Neither NAFLD
activity score (NAS) nor SAF activity score is influ-
enced by portal inflammation or fibrosis. The NAS is
related to the probability of NASH; however, definite
NASH cannot be inferred from the NAS alone.(30)
Histological diagnosis of NASH has been linked to
risk of disease progression and is sensitive to change
TABLE 3. A Comparison of the Histological Schema for
Diagnosing NASH
Criteria NASH CRN SAF Goodman
Objective/subjective Both Both. Both
Quantifiable Yes Yes Yes
Sensitive to change Yes Unknown Unknown
Externally reproducible Yes Yes No
Used in clinical trials Multiple None None
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(Table 3).(9,31,32) In the Goodman classification,
NASH is diagnosed by hepatic steatosis accompanied
by either (1) centrilobular inflammation and/or
Mallory-Denk bodies or (2) centrilobular pericellular/
perisinusoidal fibrosis or bridging fibrosis.(8) This defi-
nition was a better predictor of liver-related mortality
than the NASH CRN system, consistent with recog-
nition that fibrosis is a primary driver of liver-related
mortality. However, whether improvement in NASH
disease activity related to effective therapy can be
assessed by composite scores including noninvasive
measures of fibrosis remains unknown. Additional data
linking different diagnostic criteria to clinically mean-
ingful outcomes are needed to validate entry and
response criteria, as generally acceptable surrogates for
regulatory purposes.
DISEASE ACTIVITY
Disease activity refers to histological findings reflec-
tive of activation of disease pathways driving the dis-
ease toward cirrhosis. The NAS grades steatosis (0-3),
lobular inflammation (0-2), and ballooning (0-2).
It has been validated in terms of intraobserver and
interobserver variability and sensitivity to change
(Table 3)(6,31,32) but has not yet been shown to relate
to clinical outcomes. The activity score component of
the SAF is the sum of lobular inflammation and bal-
looning but does not include steatosis.(7) It has not
been tested against outcomes in prospective, ade-
quately powered, long-term trials. The two systems are
comparable in terms of observer variation if expert his-
topathologists are used. The Goodman classification
has not been externally validated.
STAGING
The NASH CRN system categorizes fibrosis pro-
gressively from early fibrosis (stages 1a, 1b, 1c, 2; Sup-
porting Table S1) to bridging (stage 3) and cirrhosis
(stage 4). The NASH CRN fibrosis staging system has
been validated with respect to intraobserver and inter-
observer concordance and sensitivity to change.(31,32)
No data indicate the NASH CRN subclassifications of
stage 1 fibrosis into 1a, 1b, and 1c are linked to risk of
fibrosis progression or clinical outcomes. In the Good-
man classification, fibrosis is subdivided into portal
fibrosis, bridging fibrosis, or cirrhosis with additional
subcategories (Supporting Table S1).(8) This is not yet
externally validated. Similarly, quantitative assessment
of fibrosis content by morphometry needs additional
data in NASH. For purposes of clinical trials, precir-
rhosis stages of NASH are defined by the presence of
steatohepatitis with fibrosis stage 3.
CLINICAL PHENOTYPE
The clinical phenotype of NASH is similar to non-
NASH, and there are no clinical features that differen-
tiate between non-NASH and NASH. The likelihood
of NASH and advanced fibrosis increases with age,
body mass index, presence of type 2 diabetes mellitus,
and metabolic syndrome.(14,15) There are no data relat-
ing the duration of these conditions with the likelihood
of definite NASH.
NONINVASIVE METHODS
Liver biopsy is subject to sampling variability(33);
however, there are no noninvasive tools to diagnose
NASH with enough accuracy to serve as stand-alone
entry criteria for advanced-phase trials to avoid using
histology-based endpoints(34) (Supporting Table S3).
For instance, the sensitivity and specificity of
cytokeratin-18 fragments for detecting NASH are
58% and 68%, respectively, making this an unaccept-
able diagnostic tool from a regulatory perspective.(35)
Most clinical trials focus on subjects with NASH with
some degree of fibrosis due to logistical challenges of
demonstrating clinically meaningful benefit in those
without fibrosis, who have a very low rate of progres-
sion to cirrhosis and liver-related outcomes.(2) More-
over, if improvement in fibrosis is sought, then some
degree of fibrosis is needed at trial entry.
The elements identifying the population of interest
are NASH and fibrosis stage. As noted, no noninvasive
laboratory biomarkers can reliably identify the presence
of NASH. Noninvasive fibrosis models including aspar-
tate aminotransferase (AST)-to-platelet ratio index,
FIB4, FibroTest, FibroMeterNAFLD, FibroMeterV2G,
NAFLD fibrosis score, and enhanced liver fibrosis score
all have a high negative predictive value (>80%) for
excluding fibrosis stage 3 (Supporting Table S4).(36,37)
However, the reliability of these methods is greatly
decreased for differentiating various fibrosis stages and
between bridging fibrosis and cirrhosis.
The AUROCs for distinguishing F2 versus higher
fibrosis stages using VCTE are 0.79-0.87 using liver
stiffness measurement (LSM) cutoffs of 6.7-7.7
kPa.(38) The diagnostic accuracy of VCTE to distin-
guish F3 from lesser fibrosis stages is 0.77-0.98 using
cutoff values of 8.0-10.4 kPa.(38) The main drawback
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of VCTE is its high failure rate in obese patients using
the M probe, which can be circumvented by using the
XL probe.(22,39) Similarly, magnetic resonance elastog-
raphy (MRE) had an AUROC of 0.82 and 0.87 for
detecting any fibrosis and advanced fibrosis, respec-
tively.(22) Using previously reported cutoffs, VCTE
and MRE can be used to exclude the presence of cir-
rhosis in >95% of cases.(21,22) Three studies have eval-
uated the accuracy of VCTE and MRE in head-to-
head comparison.(21,22,29) MRE outperformed VCTE
for detection of any fibrosis (AUROC 0.82 versus
0.67, P5 0.012) but had similar accuracy for detecting
other fibrosis stages.(22) In patients with body mass
index 35 kg/m2, MRE had a lower failure rate than
VCTE (5% versus 19%) despite use of the XL
probe.(29) Accuracy of MRE and VCTE was similar in
patients with successful examinations; however, MRE
outperformed VCTE in detection of moderate and
advanced fibrosis when both reliable (interquartile
range/median LSM value 30% or interquartile
range/median LSM> 30% if LSM value< 7.1 kPa)
and unreliable examinations were included.
There are limited data comparing the accuracy of
VCTE and MRE, and use of one over the other can-
not be recommended.(21,22) Both VCTE and MRE
have been shown to detect cirrhosis with an AUROC
>0.9; however, sample size in MRE studies is small,
and more data are needed.(21,22,29,38)
Several studies have examined combining noninva-
sive markers of steatosis with markers of cellular injury
or fibrosis as a surrogate marker of NASH. This
approach is based on the concept that fibrosis develops
primarily in those with steatohepatitis rather than stea-
tosis, although recent identification of fibrosis develop-
ment in those with steatosis alone challenges this
assumption. A study combining CAP score >250 dB/
second, LSM> 7 kPa, and alanine aminotransferase
(ALT)> 60 IU/L identified NASH with an AUROC
of 0.81.(40) In a preliminary report of screening data
from a phase 2B trial, the presence of two or more fea-
tures of metabolic syndrome and a FIB4> 1.1 identi-
fied NASH with fibrosis, with a positive predictive
value of 88%.(41) The potential for using two FIB4 cut-
offs (to exclude those without fibrosis and to exclude
cirrhosis) along with imaging documenting the pres-
ence of steatosis to identify definite NASH with pre-
cirrhosis stages of fibrosis needs further exploration but
may be useful for population enrichment.
In summary, for phase 2B and 3 trials, liver biopsy is
required for the diagnosis of NASH. Activity and
fibrosis stage should be defined by NASH CRN
criteria. For phase 1 and 2A trials of short duration
where risks and costs of liver biopsy are not justifiable,
the following criteria can be used to define the popula-
tion of interest, realizing that the positive predictive
value is 0.70-0.80: (1) two or more features of meta-
bolic syndrome, (2) evidence of steatosis by MRI-
PDFF or CAP, and (3) evidence of>F0 fibrosis by
either VCTE (>7.0 kPa) or MRE (>2.88 kPa). Mag-
netic resonance–based methods are highly accurate and
validated for the diagnosis of steatosis or precirrhosis
stages of fibrosis. VCTE may alternatively be used
when centers without MRE capability are involved or
in exploratory studies. This approach is most applica-
ble when the agents’ safety profile can be assumed to
be excellent based on preclinical or early-phase studies
or when a drug with extensive safety data is being
repurposed for NASH.
NASH Cirrhosis
NASH with cirrhosis and cryptogenic cirrhosis due
to NASH were both considered here. Following devel-
opment of cirrhosis, subjects can remain stable and
asymptomatic before complications of cirrhosis appear.
It is important to consider how the diagnosis was
established and whether the patient meets criteria for
compensated or decompensated cirrhosis with NASH
as the etiology of the cirrhosis.
HISTOLOGY
Histology represents the current standard for diag-
nosing cirrhosis, although certain clinical features can
establish the diagnosis in the absence of histology.
Histological diagnosis of cirrhosis requires widespread
architectural disruption and annular fibrosis surround-
ing hepatocyte nodules.(6,42) According to NASH
CRN criteria, cirrhosis is described as present or
absent, while in the Goodman classification cirrhosis is
graded as absent, incomplete, or established.(6-8)
CLINICAL PHENOTYPE
Cirrhosis may be suspected in compensated subjects
from laboratory tests such as decreased platelet counts
and/or an AST/ALT ratio> 1.(43) However, an AST/
ALT ratio> 2 should raise the possibility of alternate
etiologies.(44) A clinical diagnosis can only be made if
there is accompanying portal hypertension, with the
presence of splenomegaly, varices, or other signs of
decompensation.
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AST/ALT ratio, FIB-4, BARD score, NAFLD
fibrosis score, and AST-to-platelet ratio index are useful
in identifying patients unlikely to have advanced fibrosis
(Supporting Table S4) but less useful in predicting the
presence of cirrhosis.(36) Age-adjusted thresholds for
FIB-4 and NAFLD fibrosis score further improve the
specificity of these tests.(45) There are limited data using
these models to distinguish between bridging fibrosis
and cirrhosis. FibroTest and the enhanced liver fibrosis
score have also shown high specificity in ruling out
advanced fibrosis, but utility in differentiating bridging
fibrosis and cirrhosis remains unknown.(34)
Cross-sectional imaging can provide convincing evi-
dence of cirrhosis when a nodular liver contour or evi-
dence of portal hypertension is identified; however,
absence of these does not exclude cirrhosis.
Pooled analysis of VCTE and MRE indicates that
these can detect cirrhosis with a sensitivity and specif-
icity between 63%-100% and 66%-92%, respec-
tively.(21,22,29) The threshold for distinguishing
cirrhosis from lower stages in those with NASH is
14.0 kPa using VCTE and >4.52 kPa using MRE,
but thresholds vary based on the study (Supporting
Table S5).(21) VCTE can predict the development of
portal hypertension–related complications(46); how-
ever, total subjects with cirrhosis in these studies are
low. In the absence of elastography, the appearance of
nodular liver on cross-sectional imaging had positive
predictive value and negative predictive values of 74%
and 88%, respectively.(47)
Evidence of portal hypertension in the form of collat-
erals, identified by imaging, endoscopy, or splenomeg-
aly, without portal or splenic vein thrombosis can be
used to diagnose cirrhosis in patients with chronic liver
disease.(48) Similarly, an increase in hepatic venous pres-
sure gradient (HVPG), especially> 10mm Hg, is diag-
nostic of sinusoidal portal hypertension, which may be
caused by both acute and chronic liver disease. There
are multiple caveats for the performance of high-quality
HVPG measures, and when done correctly, the results
are relatively reproducible.(48) There are limited data on
the ability of HVPG alone to diagnose cirrhosis of any
etiology, including NASH. There is a similar paucity of
rigorously performed studies on day-to-day variability of
HVPG, and even the coefficient of variation of the
measure itself when performed multiple times in succes-
sion. Available literature suggests that the coefficient of
variation is low if the procedure is executed properly.(49)
In subjects with ascites, a serum to ascites albumin
gradient of >1.1g/dL is diagnostic of sinusoidal portal
hypertension–related ascites, but this can be due to cir-
rhosis or passive congestion.(50)
COMPENSATED VERSUS
DECOMPENSATED CIRRHOSIS
The criteria for decompensated cirrhosis remain the
same as those for compensated cirrhosis except that
biopsy risks increase with development of decompen-
sation, and most clinical texts recommend against per-
cutaneous liver biopsies in those with ascites or
coagulopathy.(51) The presence of decompensation is
identified by ascites, encephalopathy, variceal hemor-
rhage, or liver function failure characterized by elevated
bilirubin level, international normalized ratio >1.4,
and decreased albumin. There are multiple caveats that
must be considered, such as increase in total bilirubin
due to biliary obstruction or Gilbert syndrome, eleva-
tion of international normalized ratio due to malnutri-
tion, or hypoalbuminemia due to nephrotic syndrome.
These must be excluded if certainty is needed to show
that changes in these indices reflect liver dysfunction.
The risk of mortality is related to the Model for
End-Stage Liver Disease (MELD) score, particularly
as it rises over 14(52); and A MELD score >14 may be
considered a manifestation of decompensated cirrhosis.
DIAGNOSIS
The current standard for identifying NASH as the
etiology of cirrhosis is histological evidence of NASH
with cirrhosis or a prior liver biopsy demonstrating
NASH and subsequent clinical or histological evidence
of progression to cirrhosis. With development of cir-
rhosis, classical histological parameters may decrease or
even disappear completely. However, on careful exami-
nation, up to 33% of patients with cryptogenic cirrho-
sis may have NASH.(53) In true cryptogenic cirrhosis
or where a recent biopsy is not available, a prior biopsy
showing NASH along with an absence of other com-
mon causes of cirrhosis may be used to infer NASH as
the cause of cirrhosis.
If recent liver histology is unavailable and cirrhosis is
diagnosed by clinical-laboratory findings, biomarkers,
and elastography, NASH as a cause of cirrhosis can be
inferred from an absence of alternate causes of cirrho-
sis, presence of NASH on a prior biopsy, or evidence
of steatosis on recent or prior imaging along with mul-
tiple risk factors for NASH such as overweight–obe-
sity, type 2 diabetes mellitus, hypertension, or
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dyslipidemia.(42) In the absence of risk factors or non-
invasive evidence of steatosis, diagnosis of NASH as
the etiology of cirrhosis is uncertain. Dyslipidemia and
hypertension can improve with progression to
cirrhosis.(54,55)
In summary, histology remains the current stan-
dard for diagnosis of NASH cirrhosis. Presence of
cirrhosis may be inferred from elastography with
increased liver stiffness along with imaging or endo-
scopic evidence of collaterals, nodular liver, or spleno-
megaly without portal or splenic vein thrombosis. In
the absence of radiographic or endoscopic evidence of
cirrhosis, a diagnosis of cirrhosis can be inferred if
patients have two or more of the following: (1)
HVPG> 6mm Hg, (2) AST/ALT ratio> 1 but< 2
and ALT< 103 the upper limit of normal, or (3)
platelet count< 150,000/mm3. Decompensated cir-
rhosis is defined by the presence of ascites, encepha-
lopathy, variceal hemorrhage, Model for End-Stage
Liver Disease score >14, or an otherwise unexplained
abnormality of 2 of bilirubin, international normal-
ized ratio, or albumin. If biopsy is not available, the
diagnosis of NASH cirrhosis may be inferred from
the following after a negative laboratory workup for
common causes of chronic liver disease (Supporting
Table S5): (1) current documentation of hepatic stea-
tosis with noninvasive profile of cirrhosis, (2) prior
biopsy showing NASH with evidence of cirrhosis, (3)
prior imaging demonstrating hepatic steatosis with
evidence of cirrhosis, or (4) two or more risk factors
for NASH with evidence of cirrhosis. The diagnosis
of cirrhosis based on prior imaging or presence of risk
factors may be suitable for early-phase clinical trials,
though the level of evidence is not strong enough to
be allowed for phase 2B or 3 trials.
Discussion
This document summarizes the current consensus
or lack thereof regarding key elements required to
diagnose phenotypes of NAFLD for clinical trials
(Table 4). The choice of specific recommendations
reflects their relationship to disease development and
progression, sensitivity, specificity, reproducibility, and
sensitivity to change. There are limited data to link
such operational definitions to clinically meaningful
outcomes; such data will be required to establish the
foundation for development of surrogate endpoints for
clinical trials that can be translated into clinical prac-
tice. The working group will revisit this topic and
update recommendations as new data on existing and/
or new biomarkers, for example, genetic polymor-
phisms, become available. Finally, a tabular format
(Supporting Table S6) representing the population
being studied in a clinical trial is presented to allow
across-trial comparison of study populations.
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Drugs
Inherited disorders
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Lipodystrophy
Short bowel
TPN
Jejunoileal bypass
*Many include one or more subsets from each of the columns. This provides a standardized format for comparison of study popula-
tions across trials.
Abbreviations: PNPLA3, patatin-like phospholipase domain containing 3; TPN, total parenteral nutrition.
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